{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Timolol&page=6",
    "query": {
      "intervention": "Timolol",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 132,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Timolol&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Timolol&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T19:50:26.263Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04149899",
      "title": "Safety and IOP-Lowering Effects of WB007",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma, Primary Open Angle",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "WB007 0.05%",
          "type": "DRUG"
        },
        {
          "name": "WB007 0.15%",
          "type": "DRUG"
        },
        {
          "name": "WB007 0.4%",
          "type": "DRUG"
        },
        {
          "name": "Timolol 0.5%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2019-11-14",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2025-03-27",
      "last_synced_at": "2026-10-18T19:50:26.263Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04149899"
    },
    {
      "nct_id": "NCT01426113",
      "title": "A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "bimatoprost ophthalmic solution formulation A",
          "type": "DRUG"
        },
        {
          "name": "timolol ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Months to 17 Years"
      },
      "enrollment_count": 6,
      "start_date": "2011-09",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2015-10-02",
      "last_synced_at": "2026-10-18T19:50:26.263Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01426113"
    },
    {
      "nct_id": "NCT00906087",
      "title": "Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Cosopt (combination eyedrop of dorzolamide and timolol)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 14,
      "start_date": "2009-08-04",
      "completion_date": "2012-07-18",
      "has_results": true,
      "last_update_posted_date": "2017-06-02",
      "last_synced_at": "2026-10-18T19:50:26.263Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00906087"
    },
    {
      "nct_id": "NCT00652106",
      "title": "Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine 0.2% ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 432,
      "start_date": "2003-06",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2008-04-03",
      "last_synced_at": "2026-10-18T19:50:26.263Z",
      "location_count": 1,
      "location_summary": "El Paso, Texas",
      "locations": [
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00652106"
    },
    {
      "nct_id": "NCT00440336",
      "title": "Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Cosopt",
          "type": "DRUG"
        },
        {
          "name": "Xalatan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advanced Glaucoma Specialists",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2006-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-03-01",
      "last_synced_at": "2026-10-18T19:50:26.263Z",
      "location_count": 1,
      "location_summary": "Reading, Massachusetts",
      "locations": [
        {
          "city": "Reading",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00440336"
    },
    {
      "nct_id": "NCT02730871",
      "title": "Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Open-angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "Brinzolamide/brimonidine vehicle",
          "type": "DRUG"
        },
        {
          "name": "Travoprost 0.004%/timolol 0.5% solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 173,
      "start_date": "2016-06-24",
      "completion_date": "2018-07-13",
      "has_results": true,
      "last_update_posted_date": "2019-05-29",
      "last_synced_at": "2026-10-18T19:50:26.263Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02730871"
    },
    {
      "nct_id": "NCT01749904",
      "title": "Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open-Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "BOL-303259-X",
          "type": "DRUG"
        },
        {
          "name": "Timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2013-01-31",
      "completion_date": "2015-09-30",
      "has_results": true,
      "last_update_posted_date": "2018-11-07",
      "last_synced_at": "2026-10-18T19:50:26.263Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01749904"
    },
    {
      "nct_id": "NCT03579160",
      "title": "Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Wound of Skin",
        "Wound Heal",
        "Surgical Wound",
        "Full Thickness Skin Graft Healing"
      ],
      "interventions": [
        {
          "name": "0.25% timolol gel with full-thickness skin grafts",
          "type": "DRUG"
        },
        {
          "name": "Vaseline dressing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2019-01-02",
      "completion_date": "2022-01-10",
      "has_results": true,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-10-18T19:50:26.263Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03579160"
    },
    {
      "nct_id": "NCT02250612",
      "title": "SYL040012, Treatment for Open Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "1 drop of 0.375% SYL040012 (bamosiran)",
          "type": "DRUG"
        },
        {
          "name": "1 drop of 0.750% SYL040012 (bamosiran)",
          "type": "DRUG"
        },
        {
          "name": "1 drop of 1.125% SYL040012 (bamosiran)",
          "type": "DRUG"
        },
        {
          "name": "1 drop of 1.5% SYL040012 (bamosiran)",
          "type": "DRUG"
        },
        {
          "name": "1 drop of 0.5 % timolol maleate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sylentis, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 184,
      "start_date": "2014-10",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2021-01-06",
      "last_synced_at": "2026-10-18T19:50:26.263Z",
      "location_count": 4,
      "location_summary": "Artesia, California • Petaluma, California • Morrow, Georgia + 1 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02250612"
    },
    {
      "nct_id": "NCT01147601",
      "title": "Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hemangioma",
        "Infant"
      ],
      "interventions": [
        {
          "name": "topical 0.5% Timolol",
          "type": "DRUG"
        },
        {
          "name": "Control (placebo) group",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "8 Months",
        "sex": "ALL",
        "summary": "1 Month to 8 Months"
      },
      "enrollment_count": 6,
      "start_date": "2010-03",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-07-05",
      "last_synced_at": "2026-10-18T19:50:26.263Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147601"
    }
  ]
}